EGFR and cancer: Given these combined results, we urge oncologists not to empirically start advanced NSCLC patients on ICI therapy until the oncogene status of their cancer is known, as inadvertent ICI treatment of EGFRm NSCLC will increase the risk of severe TRAEs on subsequent EGFR TKI therapy.